FREE Daily Stock Alerts From Stock-PR.com
Pluristem Therapeutics, Inc. (Nasdaq:PSTI) announced that animal studies it has conducted suggest that its PLacental eXpanded (NYSEMKT:PLX) cells are potentially effective in treating life threatening hematopoietic complications associated with Acute Radiation Syndrome (NYSE:ARS). Animals were exposed to lethal doses of radiation and on the following day injected intravenously with either PLX cells or a placebo containing no cells. Nine days following treatment with the PLX cells, the animals' bone marrow and spleen were examined for signs of hematopoietic (blood forming) tissue. On day 23, bone marrow and blood samples were examined in the surviving animals. Overall survival and body weight changes were also monitored.
Read more at : http://stock-pr.com/?p=19861